{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:40:35Z","timestamp":1784288435232,"version":"3.55.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Highly effective glycoconjugate vaccines exist against four of the five major pathogenic groups of meningococci: A, C, W-135, and Y. An equivalent vaccine against group B meningococci (menB) has remained elusive due to the poorly immunogenic capsular polysaccharide. A promising alternative, the investigational recombinant menB (rMenB)- outer membrane vesicle (OMV) vaccine, contains fHBP, NHBA (previously GNA2132), NadA, and outer membrane vesicles (OMVs) from the New Zealand MeNZB vaccine. MenB currently accounts for 90% of meningococcal disease in England and Wales, where the multilocus sequence type (ST) 269 (ST269) clonal complex (cc269) has recently expanded to account for a third of menB cases. To assess the potential cc269 coverage of the rMenB-OMV vaccine, English and Welsh cc269 isolates from the past decade were genetically characterized with respect to fHBP, NHBA, and NadA. All of the isolates harbored\n            <jats:italic>fHbp<\/jats:italic>\n            and\n            <jats:italic>nhba<\/jats:italic>\n            alleles, while 98% of the cc269 isolates were devoid of\n            <jats:italic>nadA<\/jats:italic>\n            . Subvariant profiling of\n            <jats:italic>fHbp<\/jats:italic>\n            ,\n            <jats:italic>nhba<\/jats:italic>\n            , and\n            <jats:italic>porA<\/jats:italic>\n            against STs revealed the presence of two broadly distinct and well-defined clusters of isolates, centered around ST269 and ST275, respectively. An additional molecular marker, insertion sequence IS\n            <jats:italic>1301<\/jats:italic>\n            , was found to be present in 100% and &lt;2% of isolates of the respective clusters. On the basis of the genetic data, the potential rMenB-OMV coverage of cc269 in England and Wales is high (up to 100%) within both clusters. Expression studies and serum bactericidal antibody assays will serve to enhance predictions of coverage and will augment ongoing studies regarding the significance of IS\n            <jats:italic>1301<\/jats:italic>\n            within the ST269 cluster.\n          <\/jats:p>","DOI":"10.1128\/jcm.00936-09","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T01:46:38Z","timestamp":1253151998000},"page":"3577-3585","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":72,"title":["Characterization of\n            <i>fHbp<\/i>\n            ,\n            <i>nhba<\/i>\n            (\n            <i>gna2132<\/i>\n            ),\n            <i>nadA<\/i>\n            ,\n            <i>porA<\/i>\n            , Sequence Type (ST), and Genomic Presence of IS\n            <i>1301<\/i>\n            in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales"],"prefix":"10.1128","volume":"47","author":[{"given":"Jay","family":"Lucidarme","sequence":"first","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Comanducci","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Sienna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Findlow","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Kaczmarski","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Guiver","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Kugelberg","sequence":"additional","affiliation":[{"name":"Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Vallely","sequence":"additional","affiliation":[{"name":"University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Oster","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Sienna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Sienna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Sienna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Muzzi","sequence":"additional","affiliation":[{"name":"Novartis Vaccines, Sienna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph M.","family":"Tang","sequence":"additional","affiliation":[{"name":"Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Health Protection Agency, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.098"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"e_1_3_2_4_2","first-page":"851","volume":"6","year":"2006","unstructured":"Borrow, R., and E. Miller. 2006. Long term protection in children with meningococcal C conjugation vaccination: lessons learned. Expert Rev. Vaccines6:851-857.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)00037-N"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.7.4217-4223.2004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020407"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01322-06"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.186.5.1518-1530.2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.4.2088-2100.2004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46288-0"},{"key":"e_1_3_2_13_2","first-page":"95","volume":"41","year":"1999","unstructured":"Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT. Nucleic Acids Symp.41:95-98.","journal-title":"Nucleic Acids Symp."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00347.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.11.006"},{"key":"e_1_3_2_16_2","unstructured":"Int. Pathogenic Neisseria Conf. 2008"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm147"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00403-08"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.501"},{"key":"e_1_3_2_20_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021911"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.075"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/600141"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.01056.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.01.056"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7566"},{"key":"e_1_3_2_29_2","first-page":"65","volume":"72","year":"2005","unstructured":"Segal, S., and A. J. Pollard. 2005. Vaccines against bacterial meningitis. Br. Med. Bull.72:65-81.","journal-title":"Br. Med. Bull."},{"key":"e_1_3_2_30_2","first-page":"U1015","volume":"117","year":"2004","unstructured":"Sexton, K., D. Lennon, P. Oster, S. Crengle, D. Martin, K. Mulholland, T. Percival, S. Reid, J. Stewart, and J. O'Hallahan. 2004. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N. Z. Med. J.117:U1015.","journal-title":"N. Z. Med. J."},{"key":"e_1_3_2_31_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-207.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/molbev\/msm092"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1809"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072577"},{"key":"e_1_3_2_36_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/379375"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01108-08"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/126.5.514"},{"key":"e_1_3_2_40_2","unstructured":"Int. Pathogenic Neisseria Conf. 2008"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00936-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00936-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T06:46:26Z","timestamp":1646462786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00936-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1128\/JCM.00936-09"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00936-09","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"2009-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-08-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}